Price
No data yet.
Social Signal Score
Revenue
$40.08MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel W. Paterson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Beta
- 0.29
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -8.16
Financials
Revenue
$40.08M+300.8%Net Income
$-34.67MEBITDA
$-33.22MFree Cash Flow
$-43.91MEPS (diluted)
$-0.35Shares Outstanding (diluted)
100.12M+3147.7%Operating Expenses
$68.75MCash & Debt
$136.35MReturn of Capital
$0.00Revenue by Segment (annual)
$5.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $30.91M | $-209.47M | $-3.02 |
| 2024 | $10.00M | $-130.64M | $-3.66 |
| 2023 | $0.00 | $-87.37M | $-3.96 |
| 2022 | $2.60M | $-73.81M | $-4.57 |
| 2021 | $2.05M | $-71.20M | $-4.92 |
| 2020 | $88.52M | $-67.73M | $-5.28 |
| 2019 | $17.46M | $-149.21M | $-24.01 |
| 2018 | $26.72M | $-72.43M | $-13.44 |
| 2017 | $0.00 | $-67.80M | $-21.18 |
| 2016 | $0.00 | $-36.44M | $-11.82 |
| 2015 | $0.00 | $-57.87M | $-19.32 |
| 2014 | $0.00 | $-53.37M | $-24.82 |
| 2013 | $0.00 | $-41.20M | $-21.80 |
| 2012 | $0.00 | $-31.98M | $-20.45 |
Valuation
VSTMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (2)
- Newsbusinesswire.com·5h ago·Positive
Verastem Oncology to Participate in Upcoming September Investor Conferences BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: S…
View source ↗ - Newsseekingalpha.com·2d ago·Positive
…stem is evolving from a speculative biotech into a commercially validated precision oncology company, leveraging AVMAPKI FAKZYNJA revenue to fund KRAS G12D programs. VSTM's AVMAPKI FAKZYNJA launch demonstrates strong product-market fit, with $43.7M H1 2026 revenue and growing prescriber adoption in a rare disease market. The October 2026 VS-7375 data update is a pivotal catalyst; positive results could unlock multibillion-dollar KRAS G12D markets in pancreatic, lung, and colorectal cancer.
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $-0.44 per share
Typical surprise +18.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.35 vs $-0.43beat
- Thu, May 7$-0.37 vs $-0.46beat
- Wed, Mar 4$-0.39 vs $-0.49beat
- Tue, Nov 4$-1.35 vs $-0.51miss
- Thu, Aug 7$-0.39 vs $-0.85beat
- Tue, May 13$-0.96 vs $-0.72miss
Estimates and results for VSTM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VSTM officers and directors.
- Bought
- —
- Sold
- $1.6m
0 trades
59 trades
- Paterson Dansold
- Paterson Dansold
- Calkins Danielsold
- Calkins Danielsold
- Paterson Dansold
- Paterson Dansold
- Paterson Dansold
- Calkins Danielsold
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.